Skip to content

68Ga-NOTA-G3-NGR2 PET/CT's sensitivity for the patients with gastric cancer who were suffering from liver metastasis

68Ga-NOTA-G3-NGR2 PET/CT's sensitivity for the patients with gastric cancer who were suffering from liver metastasis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-DCD-15006384
Enrollment
Unknown
Registered
2015-05-11
Start date
2015-05-15
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer

Interventions

Gold Standard:
Index test:

Sponsors

The Digestive Disease hospital of Xijing hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1. The patients were diagnosed with colorectal cancer by endoscope and pathology, who had reached an advanced stage; 2. The patients with liver metastasis and no operation and other treatments; 3. No chemotherapy,radiotherapy and so on at least 1 month; 4. The patients could tolerate the pute chemotherapy and the associated chemotherapy with no contraindication; 5. No contraindication for CT and 68Ga-NOTA-G3-NGR2 PET/CT; 6. All patients should sign the informed consent of clinic trial with a voluntary heart.

Exclusion criteria

Exclusion criteria: Exclusion criteria: 1. The patients who accepted the treatment, like chemotherapy,radiotherapy and so on in 4 weeks; 2. Useing the other trial drugs; 3. Irritability and can not tolerate; 4. As the researcher estimate, the patients with serious disease and other trouble or bad compliance will go away; 5. Pregnancy or lactation; 6. The patients who can not sign the informed consent of clinic trial or drop out or vanish with no message; 7. The expected lifetime is less than half a year.

Design outcomes

Primary

MeasureTime frame
RECIST1.1;SUV;

Countries

China

Contacts

Public ContactXin Wang
wangx@fmmu.edu.cn+86 13571826689

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026